Most breast cancer metastases in bone form osteolytic lesions, but the mechanisms of tumor-induced bone resorption and destruction are not fully understood. Although it is well recognized that Wnt/b-catenin signaling is important for breast cancer tumorigenesis, the role of this pathway in breast cancer bone metastasis is unclear. Dickkopf1 (Dkk1) is a secreted Wnt/b-catenin antagonist.
Bone is an active tissue that is maintained by a balance of cellular activities carried out by specialized cell types. The osteoblasts are responsible for bone formation. Osteoblasts synthesize and secrete most proteins of the bone extracellular matrix (ECM) and express proteins that are both necessary and sufficient to induce mineralization of this specialized ECM. The osteoclasts are multinucleated cells responsible for bone resorption. Importantly, the differentiation of osteoclasts is regulated by osteoblasts. 1 The receptor activator of NF-kappaB ligand (RANKL) is expressed by osteoblastic cells and promotes osteoclast differentiation and activity through interaction with its cognate signaling receptor RANK on the cell surface of hematopoietic cells. 2, 3 This process is regulated by osteoprotegerin (OPG), a secreted decoy receptor of RANKL that binds to and inhibits the activity of RANKL. The important roles that RANKL, RANK and OPG play in the control of osteoclast formation have been firmly established. 4 The Wnt/b-catenin signaling pathway is involved in various differentiation events during embryonic development and, when aberrantly activated, can lead to tumor formation. [5] [6] [7] [8] [9] In recent years, Wnt/b-catenin signaling has been shown to play a substantial role in the control of bone mass and is involved in many disorders of bone. 9 Modulation of Wnt/b-catenin signaling in mesenchymal progenitors and osteoblasts has revealed that this pathway controls osteoblast differentiation and is critical for bone homeostasis during postnatal development. [10] [11] [12] [13] [14] The Wnt target gene OPG is of particular interest in bone metabolism, as OPG expression was found to be upregulated by Wnt/b-catenin signaling in an in vitro screen for Wnt-regulated genes in a multipotent mesenchymal cell line. 15 Moreover, cellular and molecular studies demonstrated that OPG is a direct target gene of the b-catenin-TCF complex in osteoblasts. 13 Bone metastasis is a frequent complication of cancer. [16] [17] [18] In the case of breast cancer, up to 70% of patients with advanced disease develop osteolytic bone metastases, which are a common cause of morbidity and sometimes mortality. Recent studies from multiple myeloma and prostate cancer have implicated an important role of Wnt/b-catenin signaling in bone metastasis from these cancers. [19] [20] [21] [22] [23] [24] [25] [26] [27] It has been reported that myeloma cells express the Wnt/b-catenin signaling antagonist Dickkopf1 (Dkk1) and that the presence of high levels of Dkk1 correlates with focal bone lesions in patients with myeloma. 19 For prostate cancer, it has been demonstrated that tumor cell-produced Wnts act in a paracrine fashion to induce osteoblastic activity in prostate cancer bone metastasis. 20 Although it is well recognized that Wnt/b-catenin signaling is important for breast cancer tumorigenesis, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] the role of this pathway in breast cancer bone metastasis has never been studied. In this report, we studied the expression of Dkk1 in human breast cancer tissues and cultured breast cancer cells and examined the roles of breast cancer-produced Dkk1 in osteoblastic differentiation and OPG expression. Our data suggest that Dkk1 may be a critical contributor to the process of breast cancer osteolytic bone metastasis.
Material and methods
Cell culture and conditioned media MCF-7 cells, C2C12 cells, Wnt3A-secreting L cells and control L cells were obtained from American Type Culture Collection. MDA-MB-231/bone and the parent MDA-MB-231 cells have been described before. 40 Wnt3A-secreting L cells and control L cells were cultured in Dulbecco's minimum essential medium containing 10% fetal bovine serum, 2 mM L-glutamine, 100 units/ ml penicillin, 100 lg/ml streptomycin and 350 lg/ml G418 and maintained at 37°C in humidified air containing 5% CO 2 . MCF-7 cells, MDA-MB-231 cells, MDA-MB-231/bone cells and L cells were cultured in Dulbecco's minimum essential medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ ml penicillin, and 100 lg/ml streptomycin. Wnt3A-conditioned medium (CM) and L cell control CM were prepared according to manufacturer's specifications. For breast cancer cell CM, MCF-7 cells, MDA-MB-231 cells or MDA-MB-231/bone cells were cultured in 15-cm dishes. After the cells reached confluence, the media were changed to fresh Dulbecco's minimum essential medium containing 10% fetal bovine serum for 24 hr. After further 48 hr incubation, the media were collected, centrifuged to remove cell debris, and stored at 280°C.
Knockdown of Dkk1 expression
A vector-based short hairpin RNA (shRNA) method was used to generate MDA-MB-231 cells with inhibited Dkk1 expression. The preparation of Dkk1 shRNA and control vectors has been described before. 20 Dkk1 shRNA and control were transfected into human MDA-MB-231 breast cancer cells using FuGENE 6 (Roche) according to manufacturer's specifications. Individual clones were selected with 100 lg/ml of Zeocin (Invitrogen). The Dkk1 levels in cell lysates and cell culture CM were determined by Western blotting using a specific Dkk1 antibody.
Real-time RT-PCR
TissueScan Breast Cancer Tissue qPCR Array I (BCRT501) was purchased from Origene. The product contains first-strand cDNAs prepared from 48 human breast tissues including both malignant and normal controls. These 48 cDNAs have been normalized against b-actin by RT-PCR, and arrayed onto PCR plates. Human Dkk1 real-time primer set (PPG01752B) was from SuperArray. Dkk1 expression was quantitatively measured by real-time PCR using SYBR Green (Invitrogen) in a total volume of 30 ll over 42 two-step cycles using the following temperature protocol: 95°C for 15 sec and 55°C for 60 sec. For analysis of RANKL expression in C2C12 cells, total RNA was isolated using RNABee reagent (Tel-Test); first-strand cDNA synthesis was performed using ProSTARTM Ultro HF RT-PCR Kit (Strategene) primed with oligo(dT) primer in a 10 ll reaction mixture containing 0.5 lg total RNA, and real-time RT-PCR for RANKL mRNA was performed as described in Ref. 41 
Western blotting
Cells in 6-well plates were lysed in 0.5 ml of lysis buffer (phosphate-buffered saline containing 1% Triton X-100 and 1 mM PMSF) at 4°C for 30 min. Equal quantities of protein were sub- jected to SDS-PAGE under reducing conditions. Following the transfer to immobilon-P transfer membrane, successive incubations with either anti-Dkk1 (R&D Systems), anti-b-catenin (BD Biosciences), anti-OPG (R&D systems), anti-Axin2 (Cell Signaling) or anti-actin (Sigma) and horseradish peroxidase-conjugated secondary antibody were carried out for 60-120 min at room temperature. The immunoreactive proteins were then detected using the ECL system. Films showing immunoreactive bands were scanned by Kodak Digital Science DC120 Zoom Digital Camera and analyzed with Kodak Digital Science1D Image Analysis Software.
GST-E-cadherin binding assay
Plasmid pGST-E-cadherin was provided by Dr. Gail Johnson (University of Alabama at Birmingham, Alabama). The GST-Ecadherin binding assay was carried out exactly as previously described. [42] [43] [44] Uncomplexed b-catenin present in 100 lg of total cell lysate was subjected to SDS-PAGE and detected using a monoclonal antibody to b-catenin.
Alkaline phosphatase activity assay C2C12 cells in 12-well plates were treated with Wnt3A CM, breast cancer cell CM, and anti-Dkk1 IgG (R&D Systems), as described in each figure legend. Cells were harvested 48 hr later for assay of alkaline phosphatase (ALP) activity (Pierce) by determining the amount of p-nitrophenol synthesized from p-nitrophenylphosphate according to the manufacturer's specifications. Cell lysates were analyzed for protein content using a Bio-Rad protein assay kit, and ALP activity was normalized to total protein content in each well.
Cell proliferation assay
Cells were seeded into 96-well tissue culture microtiter plates at a density of 5,000 cells/well. After 24 hr incubation, cells were treated with 25% of breast cancer CM for 72 hr. Cell proliferation was measured by the MTT assay kit (Promega).
Results

Dkk1 is frequently upregulated in human breast malignant tissues
To examine whether Dkk1 overexpression is a frequent event in human breast cancer, we analyzed Dkk1 expression in breast cancer tissues by quantitative real-time RT-PCR, using a Breast Cancer TissueScan Real-Time qPCR Arrays (Origene). This array contains 7 normal control breast tissues and 41 breast cancer tissues representing different clinical stages. All the samples were from female patients with ages ranging from 31 to 75. Pathological information including hormone receptor status is provided for each sample. As seen in Fig. 1a , we found that Dkk1 expression was low in all 7 control samples, whereas about 50% of the breast cancer tissues exhibited high levels of Dkk1. It is interesting to note that high levels of Dkk1 expression were overrepresented in estrogen receptor (ER)/progesterone receptor (PR)-double negative breast tumors (Fig. 1b) , suggesting that Dkk1 is preferentially expressed in hormone-resistant breast tumors, which typically have poorer prognosis. Together, these results indicate that Dkk1 overexpression is a frequent event in human breast cancer.
Dkk1 is upregulated in human breast bone metastatic cancer cells
Breast cancer MDA-MB-231 cells form typical osteolytic bone metastases when inoculated into the arterial circulation of mice. 40, [45] [46] [47] MDA-MB-231/bone is a subpopulation of MDA-MB-231 that was isolated by in vivo selection. 48 MDA-MB-231/ bone cells exclusively metastasize to bone with larger osteolytic lesions than the parent MDA-MB-231 cells. 48 To explore the role of Dkk1 in breast cancer bone metastases, we examined Dkk1 expression in MDA-MB-231 and MDA-MB-231/bone cells. We found that MDA-MB-231/bone cells exhibited higher levels of Dkk1 expression and Dkk1 secretion into the conditioned media than the parent MDA-MB-231 cells (Fig. 2a) . Quantification of the Western blot signals revealed that the levels of Dkk1 in CM and total cellular Dkk1 in MDA-MB-231/bone cells were 4.5-fold and 3.1-fold higher than those in the parent MDA-MB-231 cells, respectively. MCF-7 is another breast cancer cell line that is commonly used for bone metastasis studies. However, MCF-7 cells display lower metastatic activity and form smaller bone osteolytic lesions than MDA-MB-231 cells. [49] [50] [51] [52] Interestingly, we also found that MCF-7 cells displayed lower levels of Dkk1 expression and Dkk1 secretion than MDA-MB-231 cells (Fig. 2a) . Quantification of the Western blot signals revealed that the levels of Dkk1 in CM and total cellular Dkk1 in MDA-MB-231 cells were 3.3-fold and 2.7-fold higher than those in MCF-7 cells, respectively. Together, our results suggest that breast cancer cells with high levels of metastatic activity exhibit high levels of Dkk1 expression and secretion.
Induction of Dkk1 expression by activation of Wnt/b-catenin signaling in breast cancer cells
It has been recently demonstrated that Dkk1 is a direct downstream target of Wnt/b-catenin signaling in several cell line models. [53] [54] [55] Wnt/b-catenin signaling is overactivated in breast cancer. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] At the heart of the Wnt/b-catenin pathway is the stabilization of cytosolic b-catenin, which binds to transcription factors of the T-cell factor/lymphoid enhancing factor (TCF/LEF) family, leading to the transcription of Wnt/b-catenin target genes. Using the GST-E-cadherin binding assay and subsequent Western blotting, [42] [43] [44] we examined cytosolic free b-catenin levels as a measure of Wnt/b-catenin signaling activation. We found that MDA-MB-231/bone cells exhibited the highest level of uncomplexed cytosolic b-catenin (free b-catenin), while MCF-7 cells displayed the lowest level of free b-catenin (Fig. 2b) . Quantification of the Western blot signals revealed that the levels of free b-catenin in MDA-MB-231/bone cells were 31-fold and 4.4-fold higher than those in MCF-7 and MDA-MB-231 cells, respectively.
Axin2 is a specific transcriptional target of the Wnt/b-catenin signaling pathway. It is well recognized that the expression level of Axin2 is a signature of the activation of the Wnt/b-catenin signaling pathway. [56] [57] [58] [59] To further examine the activation of Wnt/b-catenin signaling in breast cancer cells, we studied Axin2 expression by Western blotting. As expected, MDA-MB-231/bone cells exhibited the highest level of Axin2 expression, while MCF-7 cells displayed the lowest level of Axin2 expression (Fig. 2b) . Quantification of the Western blot signals revealed that the levels of Axin2 in MDA-MB-231/bone cells were 6.5-fold and 3.2-fold higher than those in MCF-7 and MDA-MB-231 cells, respectively.
Previous studies have shown that Wnt3A is a canonical Wnt ligand that binds to the low density lipoprotein receptor-related proteins (LRP) and frizzled receptors, leading to the activation of Wnt/ b-catenin signaling. 60 To confirm that Dkk1 expression is upregulated via Wnt/b-catenin signaling in human breast cancer cells, we treated MDA-MB-231 cells with either L cell Wnt3A CM or control CM. As shown in Figures 3a and 3b , treatment of MDA-MB-231 cells with Wnt3A CM significantly increased free b-catenin level and Axin2 expression. Quantification of the Western blot signals of free b-catenin and Axin2 revealed 18-fold and 3.9-fold increases when compared with control cells, respectively. Consistent with the activation of Wnt/b-catenin signaling by Wnt3A, the levels of endogenous Dkk1 in total cellular lysates and those secreted into the conditioned media were significantly increased (Fig. 3c) .
Effects of breast cancer cell CM on C2C12 cell proliferation C2C12 cells are uncommitted mesenchymal progenitor cells that can be differentiated into osteoblasts upon activation of Wnt/ b-catenin signaling. 19 We employed C2C12 cells to examine the effects of breast cancer-produced Dkk1 on osteoblast proliferation, differentiation and function. As shown in Figure 4 , breast cancer cell CM slightly decreased the growth of C2C12 cells at 72 hr treatment. Furthermore, there was no significant difference of C2C12 cell proliferation after the cells were treated with different breast cancer cell conditioned media. 
Breast cancer cell-produced Dkk1 blocks Wnt3A-induced osteoblastic differentiation of C2C12 cells
Wnt3A can induce differentiation of uncommitted mesenchymal progenitor-cells into osteoblasts through the activation of Wnt/b-catenin signaling. 19 Wnt3A are expressed in osteoblasts and several breast cancer cell lines. 14, 43 To determine whether breast cancer cell-produced Dkk1 affects Wnt3A-induced osteoblastic differentiation, we examined the activity of alkaline phosphatase (ALP), a specific marker of osteoblast differentiation, in C2C12 cells. It was found that only small amounts of ALP were detectable in C2C12 cells without Wnt3A stimulation, and that breast cancer cell CM alone had no effects on basal level of ALP activity in C2C12 cells (Fig. 5a ). On the other hand, treatment of C2C12 cells with media containing Wnt3A CM for 2 days greatly induced ALP expression, which was blocked by recombinant Dkk1 protein (Fig. 5a) . Interestingly, conditioned media from MDA-MB-231 cells or MDA-MB-231/bone cells, but not from MCF-7 cells, inhibited the Wnt3A-induced ALP production in C2C12 cells (Fig. 5b) . More importantly, this effect on ALP production was neutralized by a polyclonal anti-Dkk1 antibody but not by a nonspecific polyclonal goat IgG (Figs. 5c and 5d ).
Breast cancer cell-produced Dkk1 blocks Wnt3A-induced OPG expression in C2C12 cells
Recent studies have demonstrated that OPG is a direct target gene of Wnt/b-catenin signaling in osteoblasts and that Wnt/bcatenin signaling controls bone resorption by directly regulating RANKL/RANK/OPG signaling activity. [10] [11] [12] [13] [14] To determine whether breast cancer cell-produced Dkk1 affects Wnt3A-induced OPG expression in osteoblasts, we examined OPG expression in C2C12 cells. It was found that OPG was nearly undetectable in C2C12 cells without Wnt3A stimulation and that breast cancer cell CM alone had no significant effect on basal level of OPG expression in C2C12 cells (Fig. 6a) . On the other hand, treatment of C2C12 cells with Wnt3A CM for 2 days greatly induced OPG expression, which was completely blocked by recombinant Dkk1 protein (Fig. 6a) . As expected, conditioned medium from MDA-MB-231 cells or MDA-MB-231/bone cells, but not from MCF-7 cells, inhibited Wnt3A-induced OPG expression in C2C12 cells (Fig. 6b) . Quantification of the Western blot signals revealed that OPG expression was reduced to 25% and 12% after C2C12 cells were treated with MDA-MB-231 CM and MDA-MB-231 CM, respectively. Furthermore, this effect on OPG expression was neutralized by a polyclonal anti-Dkk1 antibody but not by a nonspecific polyclonal goat IgG (Fig. 6c) .
Breast cancer cell CM blocked Wnt3A-induced RANKL reduction in C2C12 cells
Recent studies have demonstrated that expression of RANKL, another key player of the RANK/RANKL/OPG signaling pathway, is also regulated by Wnt/b-catenin signaling in osteoblasts. 12, 14, 41 To determine whether breast cancer cell CM affects RANKL expression in osteoblasts, we examined RANKL mRNA by real-time RT-PCR in C2C12 cells. As shown in Fig. 7a , breast cancer cell CM alone had no significant effect on basal level of RANKL expression in C2C12 cells. Treatment of C2C12 cells with Wnt3A CM for 3 days resulted in a significant decrease in RANKL expression, which was blocked by recombinant Dkk1 protein (Fig. 7a) . Importantly, conditioned media from MDA-MB-231/bone cells were also able to block the Wnt3A-induced RANKL reduction in C2C12 cells, although conditioned media from MDA-MB-231 cells only partially blocked the Wnt3A-induced RANKL reduction (Fig. 7b) .
MDA-MB-231 cells with Dkk1 knockdown are unable to block Wnt3A-induced C2C12 cell osteoblastic differentiation and OPG expression
To further define the roles of breast cancer-produced Dkk1 in osteoblast differentiation and OPG expression, we stably expressed a Dkk1 shRNA 20 in MDA-MB-231 cells. Figure 8a shows that a single MDA-MB-231 clone stably transfected with Dkk1-shRNA exhibited significant downregulation of the Dkk1 protein in the conditioned media. Quantification of the Western blot signals revealed that Dkk1 in CM and total cellular Dkk1 in MDA-MB-231 Dkk1-shRNA cells were reduced to 8% and 17% than those in control cells, respectively. Moreover, conditioned media from MDA-MB-231 Dkk1-shRNA cells failed to block Wnt3A-induced ALP production (Fig. 8b ) and OPG expression (Fig. 8c) . Taken together, these results show that reducing the expression of the Wnt/b-catenin signaling inhibitor Dkk1 unmasked an osteoinductive effect in osteolytic MDA-MB-231 cells.
Discussion
Dkk1 is a secreted protein that negatively modulates the Wnt/bcatenin pathway. In contrast to other Wnt/b-catenin signaling antagonists, Dkk1 is overexpressed in many malignant tissues including breast cancer, 61 lung cancer, 62 esophageal carcinomas, 62 multiple myeloma, 19 ovarian endometrioid adenocarcinomas, 55 hepatoblastomas and Wilms' tumors. 63 In the case of breast cancer, it has been reported that Dkk1 is preferentially expressed in ER and PR-negative tumors and in tumors from women with a family history of breast cancer. 61 Furthermore, Dkk1 is a potential prognostic and diagnostic marker for cohorts of breast cancer patients with poor prognosis. 61 In the present study, by using a Breast Cancer TissueScan Real-Time qPCR array, we also found that 50% of the breast cancer tissues exhibited high levels of Dkk1 and that high levels of Dkk1 expression were overrepresented in ER/PR-double negative breast tumors. All together, these studies suggest that Dkk1 is frequently overexpressed in breast malignant tissues.
Recent studies have demonstrated that Dkk1 is not only a key inhibitor but also a direct downstream target of Wnt/b-catenin signaling. Activation of Wnt/b-catenin signaling by Wnt1 or ectopic expression of active b-catenin, TCF4 or LRP6 mutants induces transcription of the human Dkk1 gene in several cell line models in vitro. [53] [54] [55] Multiple b-catenin/TCF4 binding sites in the Dkk1 gene promoter region allow for this activation. [53] [54] [55] In the present study, we demonstrate that Wnt3A activates Wnt/b-catenin signaling and enhances Dkk1 expression in breast cancer MDA-MB-231 cells. Although genetic mutations of APC or b-catenin are rarely observed in breast cancer, compelling evidence has implicated abnormal regulation of Wnt/b-catenin signaling in tumorigenic program of breast cancer. For example, Wnt1, the founding member of the Wnt gene family, was initially identified as a mammary oncogene insertionally activated by mouse mammary tumor virus. [28] [29] [30] Overexpression of several Wnts has been reported in breast cancer. [31] [32] [33] 39 Secreted Frizzled-related protein1 (sFRP1), a member of the secreted Wnt antagonist family, is downregulated in breast cancers. 34 Upregulation of b-catenin mRNA levels was detected by microarray analysis in human breast cancer. 35 More importantly, it has been reported that b-catenin protein levels are significantly upregulated in human breast cancer tissues and correlate with poor prognosis, acting as a strong and independent prognostic factor in human breast cancer patients. [36] [37] [38] Thus, Dkk1 upregulation is likely a consequence of overactivation of Wnt/bcatenin signaling in human breast cancer. Further studies will be required to define whether Dkk1 expression is correlated with the activation of Wnt/b-catenin signaling in human breast cancer tissues. As Dkk1 is a major antagonist of Wnt/b-catenin signaling, it will be also interesting to explore the mechanism employed by human breast cancer cells that are able to escape Dkk1 inhibition.
Studies in the past several years have established that Wnt/bcatenin signaling plays a critical role in the regulation of bone mass and is a causative factor for many disorders of the bone. Osteoblast differentiation is the primary event of bone formation, characterized by the synthesis, deposition and mineralization of the extracellular matrix. One of the mechanisms whereby Wnt/bcatenin signaling increases bone formation is via stimulation of the development of osteoblasts. 9 In the present study, we demonstrate that human breast cancer cells with a predisposition toward the formation of osteolytic bone metastases exhibit increased levels of Dkk1 expression and that breast cancer cell-produced Dkk1 inhibits the Wnt3A-induced osteoblastic differentiation of osteoblast precursor C2C12 cells. These results suggest that breast cancer-produced Dkk1 is involved in breast cancer-derived osteolytic metastases.
It has been demonstrated that Wnt/b-catenin signaling in osteoblasts is able to coordinate postnatal bone acquisition by controlling the differentiation and activity of osteoclasts. OPG is a direct target gene of the b-catenin-TCF complex in osteoblasts 13, 15 and acts as a decoy receptor that blocks the binding of RANKL to its cognate signaling receptor RANK on hematopoietic cells, thereby inhibiting osteoclast formation and activity. [2] [3] [4] In the present study, we found that breast cancer cell-produced Dkk1 inhibited Wnt3A-induced OPG expression and RANKL reduction in osteoblast precursor C2C12 cells, strengthening the notion that breast cancerproduced Dkk1 could be a critical modulator for breast cancer osteolytic metastases. In the future, we should examine whether Dkk1 is frequently upregulated in human breast cancer patient serums and malignant tissues with osteolytic bone metastases.
In summary, we propose that Dkk1 expression in breast cancer cells contributes to the development and progression of breast osteolytic bone metastases. Breast cancer cells with overactivated Wnt/b-catenin signaling produce high levels of Dkk1, which blocks osteoblast differentiation, OPG expression and RANKL reduction, and, consequently, stimulates osteoclastic bone resorption. Thus, Dkk1 is a potential therapeutic target in designing pharmacologic interventions for bone metastases in breast cancer.
